Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC

被引：1
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2017年 / 59卷 / 1513期
关键词：
CELL LUNG-CANCER;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：4 / 5
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab as first-line treatment for metastatic uveal melanoma
    Ernesto Rossi
    Monica Maria Pagliara
    Daniela Orteschi
    Tommaso Dosa
    Maria Grazia Sammarco
    Carmela Grazia Caputo
    Gianluigi Petrone
    Guido Rindi
    Marcella Zollino
    Maria Antonietta Blasi
    Alessandra Cassano
    Emilio Bria
    Giampaolo Tortora
    Giovanni Schinzari
    [J]. Cancer Immunology, Immunotherapy, 2019, 68 : 1179 - 1185
  • [2] Pembrolizumab as first-line treatment for metastatic uveal melanoma
    Rossi, Ernesto
    Pagliara, Monica Maria
    Orteschi, Daniela
    Dosa, Tommaso
    Sammarco, Maria Grazia
    Caputo, Carmela Grazia
    Petrone, Gianluigi
    Rindi, Guido
    Zollino, Marcella
    Blasi, Maria Antonietta
    Cassano, Alessandra
    Bria, Emilio
    Tortora, Giampaolo
    Schinzari, Giovanni
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (07) : 1179 - 1185
  • [3] COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE
    Chouaid, C.
    Bensimon, L.
    Tardu, J.
    Millier, A.
    Insinga, R.
    Rai, A.
    Levy-Bachelot, L.
    Levy, P.
    [J]. VALUE IN HEALTH, 2020, 23 : S433 - S433
  • [4] Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
    Socinski, M. A.
    Jotte, R. M.
    Cappuzzo, F.
    Orlandi, F.
    Stroyakovskiy, D.
    Nogami, N.
    Rodriguez-Abreu, D.
    Moro-Sibilot, D.
    Thomas, C. A.
    Barlesi, F.
    Finley, G.
    Kelsch, C.
    Lee, A.
    Coleman, S.
    Deng, Y.
    Shen, Y.
    Kowanetz, M.
    Lopez-Chavez, A.
    Sandler, A.
    Reck, M.
    Ahualli, A.
    Jarchum, G.
    Kaen, D. L.
    Kahl, S.
    Kotliar, M.
    Kowalyszyn, R. D.
    Lerzo, G.
    Magri, I
    Martin, C.
    Pastor, A.
    Picon, P.
    Streich, G.
    Varela, M.
    Blinman, P.
    Boyer, M.
    Crombie, C.
    Gauden, S.
    Gill, S.
    Hughes, B.
    John, T.
    Joshi, A.
    Kosmider, S.
    Lewis, C.
    Millward, M.
    Nordman, I
    Nott, L.
    O'Byrne, K.
    Parnis, F.
    Potasz, N.
    Richardson, G.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (24): : 2288 - 2301
  • [5] Osimertinib Approved for First-Line Treatment in Metastatic NSCLC
    Schuyler, Devon
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (06) : 397 - 397
  • [6] KEYTRUDA® (Pembrolizumab) plus KISPLYX® (Lenvatinib) - First-Line Treatment of Patients with advanced Renal Cell Carcinoma
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 70 - 70
  • [7] Sarcopenia is not a useful prognostic biomarker in metastatic NSCLC patients treated with first-line pembrolizumab
    Thomson, Findlay
    Stratton, Cory
    Stares, Mark
    Ding Tze-en
    Phillips, Iain
    [J]. LUNG CANCER, 2021, 156 : S42 - S42
  • [8] Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC
    El-Ghazzi, Nathan
    Lavaud, Pernelle
    [J]. BULLETIN DU CANCER, 2021, 108 (03) : 231 - 233
  • [9] Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC
    Rijavec, Erika
    Indini, Alice
    Ghidini, Michele
    Tomasello, Gianluca
    Cattaneo, Monica
    Barbin, Francesca
    Grossi, Francesco
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (07) : 705 - 713
  • [10] Treatment options after first-line immunotherapy in metastatic NSCLC
    Santos, Edgardo S.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (03) : 221 - 228
12345